Abstract
Drug resistance is one of the major obstacles for chemotherapy and targeted therapy in lung cancer with complex mechanisms. The researches have demonstrated that epigenetic changes are closely related to drug resistance of tumor. DNA methylation is an important epigenetic modification. In this paper, the relationships between hMLH1 promoter aberrant methylation and platinum-resistance, and DAPK promoter aberrant methylation and EGFR-TKI resistance in lung cancer will be briefly reviewed. Key words: Lung neoplasms; hMLH1; DAPK; DNA methylation; Drug resistance, neoplasms
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
